- Home
- AJG vs EW Comparison
AJG vs EW Comparison
Compare AJG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AJG | EW |
|---|---|---|
| Founded | 1927 | 1958 |
| Country | United States | United States |
| Employees | 706000 | N/A |
| Industry | Specialty Insurers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4B | 50.2B |
| IPO Year | 1995 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AJG | EW |
|---|---|---|
| Price | $206.78 | $83.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $274.60 | $96.37 |
| AVG Volume (30 Days) | 1.7M | ★ 4.7M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.16 | 0.66 |
| Revenue | ★ $6,159,600,000.00 | $6,067,600,000.00 |
| Revenue This Year | $30.53 | $13.39 |
| Revenue Next Year | $9.13 | $9.81 |
| P/E Ratio | ★ $64.31 | $125.40 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $190.75 | $72.30 |
| 52 Week High | $351.23 | $87.89 |
Technical Indicators
Market Signals| Indicator | AJG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 56.06 |
| Support Level | $205.11 | $83.32 |
| Resistance Level | $228.55 | $86.95 |
| Average True Range (ATR) | 6.54 | 2.37 |
| MACD | 1.00 | 0.19 |
| Stochastic Oscillator | 80.20 | 83.87 |
Price Performance
Historical ComparisonAbout AJG Arthur J. Gallagher & Co.
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.